Povorcitinib showcases substantial total body and facial repigmentation in vitiligo in Phase 2b Trial Jacinthlyn Sylvia3 Nov 2023 9:45 AM ISTIncyte, a global biopharmaceutical company, unveiled promising results from a Phase 2b clinical trial assessing the safety and efficacy of...
Use of topical statins promising for treating disseminated superficial actinic porokeratosis Medha Baranwal2 Nov 2023 9:30 AM ISTUSA: A recent study has found that for patients with disseminated superficial actinic porokeratosis (DSAP), topical statin and cholesterol combination...
FDA approves first new biologic treatment option for hidradenitis suppurativa patients Dr. Kamal Kant Kohli1 Nov 2023 10:45 AM ISTThe US Food and Drug Administration (FDA) has approved secukinumab as first new biologic treatment option for moderate to severe hidradenitis...
Remibrutinib improves outcomes in Chronic Spontaneous Urticaria Patients Jacinthlyn Sylvia31 Oct 2023 2:30 AM ISTPatients with chronic spontaneous urticaria (CSU) who have found little relief with existing treatments, a novel drug called Remibrutinib (LOU064) has...
Treatment with apremilast safe and effective in patients with genital psoriasis: DISCREET trial Medha Baranwal30 Oct 2023 5:00 AM ISTUSA: A recent phase 3 randomized clinical trial published in the Journal of the American Academy of Dermatology has shed light on the safety and...
Maintenance dose of lebrikizumab may clear skin and improve symptoms in atopic dermatitis Dr. Kamal Kant Kohli28 Oct 2023 10:30 AM ISTResearchers have found in a new trial that Both 2-week and monthly dosing of lebrikizumab achieves skin clearance and symptoms relief in atopic...
GMC Rajouri gets dermatology wing to treat skin related cancer, diseases Kajal Rajput28 Oct 2023 7:45 AM ISTThe Medical Superintendent further added that 27 skin cancer cases like Basel Cell Carcinoma (BCC), Malignant Melanoma, Verrucous Carcinoma including...
Oral tofacitinib, novel alternative treatment for resistant alopecia areata among children Medha Baranwal27 Oct 2023 10:30 AM ISTChina: New research has demonstrated the safety and effectiveness of oral tofacitinib as a treatment option for pediatric alopecia areata (AA),...
Oral povorcitinib promising in extensive nonsegmental vitiligo at week 52 in Phase 2b clinical trial Dr. Kamal Kant Kohli26 Oct 2023 10:30 AM ISTUSA: Treatment with oral povorcitinib in adult patients with extensive nonsegmental vitiligo was associated with substantial total body and facial...
JAK inhibitor use in skin conditions associated with elevated odds of the appearance of acne: JAMA Aditi25 Oct 2023 10:30 AM ISTJAK inhibitors usage are increasing in atopic dermatitis, alopecia areata, psoriasis, and vitiligo. Studies suggest that JAK inhibitors may have...
Guselkumab efficacious among patients of psoriasis with skin of color Dr. Kamal Kant Kohli24 Oct 2023 10:15 AM ISTUSA: Guselkumab exhibited fast and significant clearance in body and scalp psoriasis after one dose in patients with skin of color in a phase 3b...
Require additional efficacy data for Dupixent approval for chronic spontaneous urticaria: USFDA to Sanofi Ruchika Sharma23 Oct 2023 4:44 PM ISTDupixent is a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways and is not an immunosuppressant.
